On Monday, Arrowhead Pharmaceuticals Inc (NASDAQ: ARWR) opened higher 4.73% from the last session, before settling in for the closing price of $14.80. Price fluctuations for ARWR have ranged from $14.23 to $30.41 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
A company in the Healthcare sector has dropped its sales by -2.87% annually for the last half of the decade. Company’s average yearly earnings per share was noted 43.28% at the time writing. With a float of $114.16 million, this company’s outstanding shares have now reached $125.57 million.
In an organization with 609 employees, it is important to assess its efficiency. In terms of profitability, gross margin is -272.28%, operating margin of -25037.88%, and the pretax margin is -25870.12%.
Arrowhead Pharmaceuticals Inc (ARWR) Insider and Institutional Ownership
A key investor’s attitude towards the stock of the Biotechnology industry is another important factor to consider. The insider ownership of Arrowhead Pharmaceuticals Inc is 16.87%, while institutional ownership is 70.71%. The most recent insider transaction that took place on Mar 13 ’25, was worth 774,975. In this transaction Chief Executive Officer of this company sold 51,425 shares at a rate of $15.07, taking the stock ownership to the 4,062,377 shares. Before that another transaction happened on Mar 13 ’25, when Company’s Officer proposed sale 51,425 for $15.07, making the entire transaction worth $774,785.
Arrowhead Pharmaceuticals Inc (ARWR) Latest Financial update
Wall Street market experts anticipate that the next fiscal year will bring earnings of -1.02 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 43.28% per share during the next fiscal year.
Arrowhead Pharmaceuticals Inc (NASDAQ: ARWR) Trading Performance Indicators
Check out the current performance indicators for Arrowhead Pharmaceuticals Inc (ARWR). In the past quarter, the stock posted a quick ratio of 6.09. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 851.37.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -5.15, a number that is poised to hit -0.20 in the next quarter and is forecasted to reach -3.76 in one year’s time.
Technical Analysis of Arrowhead Pharmaceuticals Inc (ARWR)
Let’s dig in a bit further. During the last 5-days, its volume was 1.89 million. That was inferior than the volume of 1.94 million it reported in year-ago period. As of the previous 9 days, the stock’s Stochastic %D was 36.85%. Additionally, its Average True Range was 0.96.
During the past 100 days, Arrowhead Pharmaceuticals Inc’s (ARWR) raw stochastic average was set at 9.72%, which indicates a significant decrease from 35.76% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 64.39% in the past 14 days, which was lower than the 70.38% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $18.47, while its 200-day Moving Average is $21.67. However, in the short run, Arrowhead Pharmaceuticals Inc’s stock first resistance to watch stands at $15.78. Second resistance stands at $16.06. The third major resistance level sits at $16.47. If the price goes on to break the first support level at $15.09, it is likely to go to the next support level at $14.68. The third support level lies at $14.40 if the price breaches the second support level.
Arrowhead Pharmaceuticals Inc (NASDAQ: ARWR) Key Stats
There are currently 137,317K shares outstanding in the company with a market cap of 2.13 billion. Presently, the company’s annual sales total 3,550 K according to its annual income of -599,490 K. Last quarter, the company’s sales amounted to 2,500 K and its income totaled -173,090 K.
